Anebulo awarded up to $1.9M NIDA grant for IV selonabant development

Anebulo Pharmaceuticals, Inc.

Grant from NIDA/NIH up to ~$1.9M over two years for IV selonabant as emergency treatment for acute cannabis-induced toxicities.
Initial tranche $0.9M awarded; second tranche ~$1M subject to milestone achievements.
Program targets pediatric cannabis-induced CNS depression, a serious unmet medical need.
CEO notes grant validates progress and supports IV formulation clinical testing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.